| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 69.29 mm | 69.29 mm | 69.29 mm | 69.29 mm | 69.29 mm | 69.29 mm |
| Cash burn (monthly) | 34.64 mm | 3.66 mm | 12.41 mm | 14.81 mm | 7.47 mm | 9.14 mm |
| Cash used (since last report) | 183.38 mm | 19.40 mm | 65.72 mm | 78.42 mm | 39.56 mm | 48.37 mm |
| Cash remaining | -114.09 mm | 49.89 mm | 3.57 mm | -9.12 mm | 29.73 mm | 20.92 mm |
| Runway (months of cash) | -3.3 | 13.6 | 0.3 | -0.6 | 4.0 | 2.3 |
| 13F holders | Current |
|---|---|
| Total holders | 151 |
| Opened positions | 27 |
| Closed positions | 12 |
| Increased positions | 52 |
| Reduced positions | 39 |
| 13F shares | Current |
|---|---|
| Total value | 535.97 bn |
| Total shares | 293.94 mm |
| Total puts | 65.10 k |
| Total calls | 10.90 k |
| Total put/call ratio | 6.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Frazier Life Sciences Management | 19.39 mm | $48.67 bn |
| T. Rowe Price Investment Management | 16.71 mm | $41.94 mm |
| VR Adviser | 16.22 mm | $40.70 bn |
| Venrock Healthcare Capital Partners III | 16.22 mm | $38.11 mm |
| BlackRock | 15.76 mm | $39.56 bn |
| City Hill | 12.90 mm | $36.25 mm |
| Vanguard | 12.67 mm | $31.81 bn |
| Logos Global Management | 12.50 mm | $31.38 bn |
| Suvretta Capital Management | 12.32 mm | $30.91 bn |
| Novartis Pharma | 12.31 mm | $23.14 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Feb 25 | Ebun Garner | Stock option Common Stock | Grant | Acquire A | No | No | 1.63 | 50,000 | 81.50 k | 50,000 |
| 3 Feb 25 | Jonathan E Lim | Stock option Common Stock | Grant | Acquire A | No | No | 1.76 | 2,500,000 | 4.40 mm | 2,500,000 |
| 3 Feb 25 | Ebun Garner | Stock option Common Stock | Grant | Acquire A | No | No | 1.76 | 700,000 | 1.23 mm | 700,000 |
| 3 Feb 25 | Shannon Morris | Stock option Common Stock | Grant | Acquire A | No | No | 1.76 | 780,000 | 1.37 mm | 780,000 |
| 3 Feb 25 | David M. Chacko | Stock option Common Stock | Grant | Acquire A | No | No | 1.76 | 800,000 | 1.41 mm | 800,000 |
| 13 Dec 24 | Ebun Garner | Common Stock | Other | Acquire J | No | No | 1.564 | 5,731 | 8.96 k | 21,174 |
| 13 Dec 24 | David M. Chacko | Common Stock | Other | Acquire J | No | No | 1.564 | 12,324 | 19.27 k | 262,187 |
| 14 Jun 24 | Ebun Garner | Common Stock | Other | Acquire J | No | No | 1.564 | 5,715 | 8.94 k | 21,174 |
| 14 Jun 24 | David M. Chacko | Common Stock | Other | Acquire J | No | No | 1.564 | 3,137 | 4.91 k | 262,187 |
